Business
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has entered into a securities purchase agreement with a new long-term fundamental investor for the purchase and sale of 5,000,000 shar
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"SHELTON, Conn., Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has entered into a securities purchase agreement with a new long-term fundamental investor for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.80 per share, in a registered direct offering, for gross proceeds of approximately $4 million, before deducting placement agent commissions and other offering expenses. The offering is expected to close on or about November 3, 2025, subject to the satisfaction of customary closing conditions.","length":904,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zdViy5pzlzPB_LdO71ooeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company expects to use the net proceeds from the offering for the advancement of their clinical trials, working capital and general corporate purposes. Upon closing of the offering, the Company expects it will have cash runway until the end of the first quarter of 2027.","length":274,"tagName":"p"},{"type":"text","content":"A.G.P./Alliance Global Partners is acting as the sole placement connection with the offering.","length":93,"tagName":"p"},{"type":"text","content":"This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 280681) which was declared effective by the Securities and Exchange Commission (the "SEC") on July 11, 2024. The offering...